Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Outstanding (2016 - 2025)

Altimmune (ALT) has disclosed Shares Outstanding for 16 consecutive years, with $110.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 53.25% to $110.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.9 million through Dec 2025, up 53.25% year-over-year, with the annual reading at $110.9 million for FY2025, 53.25% up from the prior year.
  • Shares Outstanding for Q4 2025 was $110.9 million at Altimmune, up from $95.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $110.9 million in Q4 2025, with the low at $38.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $61.3 million, with a median of $52.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding skyrocketed 64021712.9% in 2021, then rose 2.37% in 2024.
  • Over 5 years, Shares Outstanding stood at $41.0 million in 2021, then grew by 20.02% to $49.2 million in 2022, then soared by 43.65% to $70.7 million in 2023, then grew by 2.37% to $72.4 million in 2024, then soared by 53.25% to $110.9 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $110.9 million, $95.6 million, and $85.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.